Epizyme Announces U.S. FDA Accelerated Approval of Tazverik (tazemetostat) for Relapsed/Refractory Follicular Lymphoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2020-- Epizyme, Inc. (Nasdaq:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news